PharmaCyte Biotech

PharmaCyte Biotech

Biotechnology
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

$3.8M

Market Cap • 10/23/2026

1996

(30 years)

Founded

2003

(23 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,1

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,6

EPS

—

Market Cap

Market Cap

3,8M

EV

-24,4M

EV/Revenue

0

EV/EBITDA

3,5

EV/EBIT

3,5

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-109,5M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

13,2%

CAGR Net Income 5Y

34,3%

CAGR EPS 5Y

-49,6%

CAGR OCF 5Y

-0,4%

Leverage

N.D./EBITDA

4,4

Debt/Equity

0%

Current Ratio

40,3

Quick Ratio

40,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium